Jaguar health provides updates regarding company's focus on rare and orphan disease indications in the u.s. & europe

Rare disease indications are the sole focus of napo therapeutics, the corporation established by jaguar in italy in 2021, with an initial focus on short bowel syndrome jaguar to take the lead on microvillus inclusion disease in the u.s., with the company intending to submit an investigational new drug (ind) application to the fda for this ultra-rare disease in 1h 2023 san francisco, ca / accesswire / january 26, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today provided updates regarding the company's focus on rare and orphan disease indications: short bowel syndrome (sbs), microvillus inclusion disease (mvid), and cholera. rare disease indications are the sole focus of napo therapeutics, the corporation established by jaguar in italy in 2021, with an initial focus on sbs.
JAGX Ratings Summary
JAGX Quant Ranking